Hormone therapy in men and risk of cardiac allograft rejection.
Hormone therapy with leuprolide acetate (Lupron) is frequently used to treat prostate cancer, a common malignancy expected to be diagnosed in >180,000 men in the United States this year. In addition, testosterone supplementation is frequently recommended for adult men with reduced libido or impotence and decreased serum levels of testosterone. Although these hormone therapies are generally considered benign, we describe 3 cases of acute cardiac rejection temporally associated with the use of these drugs in men who have undergone cardiac transplantation. To our knowledge, this is the first such description of this phenomenon in the literature.
Schofield
Richard S
RS
Division of Cardiovascular Medicine and University of Florida, Shands Transplant Center, University of Florida College of Medicine, Gainesville, Florida 32610, USA. schofrs@medicine.ufl.edu
Hill
James A
JA
McGinn
Charles J
CJ
Aranda
Juan M
JM
D000208:Acute Disease; D000230:Adenocarcinoma / Q000150:complications / Q000188:drug therapy; D000368:Aged; D006084:Graft Rejection / Q000139:chemically induced* / Q000453:epidemiology*; D016027:Heart Transplantation / Q000276:immunology*; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D006801:Humans; D016729:Leuprolide / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy; D012307:Risk Factors; D013318:Stroke Volume / Q000187:drug effects; D013739:Testosterone / Q000009:adverse effects; D014481:United States / Q000453:epidemiology; D016277:Ventricular Function, Left / Q000187:drug effects
D013739:Testosterone; D016729:Leuprolide